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Abstract
BACKGROUND & AIMS—In patients with Barrett’s esophagus (BE), radiofrequency ablation
(RFA) safely and effectively eradicates dysplasia and intestinal metaplasia. We aimed to
determine the efficacy and durability of RFA for patients with dysplastic and nondysplastic BE.
METHODS—We performed a systematic review and meta-analysis of studies identified in
PubMed and EMBASE that reported the proportion of patients treated with RFA who had
complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and the proportion of
patients with recurrent IM after successful treatment. Pooled estimates of CE-D, CE-IM, IM
recurrence, and adverse events were calculated.
RESULTS—We identified 18 studies of 3802 patients reporting efficacy and 6 studies of 540
patients reporting durability. Ten were prospective cohort studies, 9 were retrospective cohort
studies, and 1 was a randomized trial. CE-IM was achieved in 78% of patients (95% confidence
interval [CI], 70%–86%) and CE-D was achieved in 91% (95% CI, 87%–95%). After eradication,
IM recurred in 13% (95% CI, 9%–18%). Progression to cancer occurred in 0.2% of patients
during treatment and in 0.7% of those after CE-IM. Esophageal stricture was the most common
adverse event and was reported in 5% of patients (95% CI, 3%–7%). Confidence in most summary
estimates was limited by a high degree of heterogeneity, which did not appear to be caused by
single outlier studies.
CONCLUSIONS—Treatment of BE with RFA results in CE-D and CE-IM in a high proportion
of patients, with few recurrences of IM after treatment and a low rate of adverse events. Despite
the large amount of study heterogeneity, these data provide additional information for patients and
providers to make informed treatment decisions.
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Barrett’s esophagus (BE) is a precancerous condition characterized by the replacement of
the normal stratified squamous epithelium of the distal esophagus by intestinal metaplasia
(IM), affecting 1%–2% of the general population.1–3 Multiple endoscopic ablative
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techniques have been developed for BE, with the goal of eradicating IM and preventing
neoplastic progression to esophageal adenocarcinoma (EAC).4–7 Of these techniques,
radiofrequency ablation (RFA) is used commonly and was shown in a randomized
controlled trial (RCT) to have low complication rates, substantial rates of complete
eradication of dysplasia (CE-D) and IM (CE-IM), and a decrease in progression to cancer.8
Although RFA is safe and effective in eradicating IM, the absolute magnitude of the benefit
has not been well described. Different studies have varied considerably in their reports of
absolute rates of CE-D and CE-IM and in estimates of durability of the neosquamous
epithelium that appears after RFA.9–11 These studies are often from tertiary care centers,
subject to local expertise with limited generalizability; have small sample sizes that limit the
precision of effect estimates; and have varied in the inclusion of different histologic grades
of BE. The latter issue is important because the risk-benefit ratio of ablation changes with
the risk of malignancy, which is tied closely to histologic grade. In addition, pretreatment
histology may predict treatment efficacy, although such a relationship has been seen
inconsistently.12,13 Inclusion of a limited histology distribution in an individual study may
not allow for adequate power to make such comparisons. Estimates of adverse events also
may be unreliable because of insufficient power in individual studies.
We therefore performed a systematic review and meta-analysis of studies of RFA for
dysplastic and nondysplastic BE (NDBE). We aimed to determine the proportion of patients
achieving CE-D and CE-IM after treatment with RFA as well as the proportion with
recurrence of IM after successful treatment. We also sought to evaluate the association of
pretreatment histology with CE-D and CE-IM and the incidence of adverse events.
Methods
Search Strategy and Eligibility Criteria
We followed the Meta-analysis Of Observational Studies in Epidemiology guidelines for the
conduct and reporting of systematic reviews of observational studies.14 Two authors (E.S.O.
and N.L.) independently searched the PubMed and EMBASE databases for relevant articles
on August 24, 2012. PubMed was queried with the search terms “((Barrett) OR Barrett’s)
AND (radiofrequency OR radio-frequency OR ablation)” and EMBASE was queried with
“Barrett AND (‘radiofrequency’/exp OR radiofrequency OR radio+frequency OR
ablation).” Abstracts identified in EMBASE that were published in 2011 and 2012 were
included. Two additional manuscripts from the authors’ institution accepted for publication
and in press at the time of the search but not yet indexed in either database also were
included.15,16
The identified records then were reviewed independently according to strict eligibility
criteria. We excluded letters to the editor; editorials; non-English language studies;
nonclinical or nonhuman studies; review articles; case reports; studies that were not
observational or RCTs; studies without biopsy-proven BE; studies that did not use focal
RFA; studies of patients who had received other ablative therapies (with the exception of
endoscopic mucosal resection [EMR] in combination with RFA); studies not reporting either
efficacy (CE-IM or CE-D) or durability (histologic recurrence after CE-IM or CE-D);
efficacy studies with mean or median follow-up periods less than 12 months from the first
RFA session; durability studies with mean or median follow-up periods less than 12 months
from the first post-RFA endoscopy showing eradication; studies with fewer than 20 subjects
receiving RFA; duplicate reports of study samples; abstracts published before 2011; and
studies not reporting a follow-up duration. Abstracts published before 2011 were excluded
because those that have not been converted into manuscript form in the 2 years after
submission may have significant flaws in methodology or interpretation that have limited
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their acceptability for publication. After exclusion of ineligible abstracts, a full-text review
of remaining studies was performed independently using the same eligibility criteria, with
discrepancies resolved by consensus. We attempted to contact study authors for clarification
when multiple reports potentially described the same patient population. For multiple reports
describing a common patient sample, we included the most recent report unless only the
older report described our a priori outcome variables. Duplicate reports were included,
however, if 1 reported efficacy outcomes and the second reported durability. After exclusion
of full-text records, the reference sections of included articles were searched manually for
additional records.
Data Collection
Data were abstracted from each study and organized into formalized evidence tables
independently by the authors. We recorded study characteristics including year of
publication, country, study design, setting, inclusion and exclusion criteria, RFA and
surveillance protocol, sample size, proton pump inhibitor use, use of circumferential RFA
and EMR, number of RFA sessions and surveillance endoscopies, and follow-up duration.
For the RFA protocols, we recorded the timing and type of RFA (circumferential vs focal).
For the surveillance protocols, we recorded intervals of surveillance endoscopy, inclusion of
cardia biopsies, and follow-up evaluation start time (ie, the time at which treatment was
considered complete, and surveillance was begun). For studies that reported both efficacy
and durability, sample size was considered separately for each outcome. Recorded patient
characteristics included age, sex, BE length, and pretreatment dysplasia assessment. The
quality of each study was assessed using the previously validated Downs and Black17
instrument, which can assess both randomized and nonrandomized studies. This tool
assesses the quality of reporting, external validity, bias, confounding, and power using a
checklist of 27 items, and scores reports from 0 to 32, with higher scores representing
greater methodologic quality. After abstraction, the authors reviewed the evidence tables and
discrepancies again were resolved by consensus.
Outcomes
The primary efficacy outcomes were CE-IM, defined as the absence of IM on endoscopy
and histology after RFA; and CE-D, defined as the absence of dysplasia on histology (in
subjects with baseline dysplastic BE). Residual IM at the gastro-esophageal junction was
considered to be failure of CE-IM in the efficacy analysis and recurrence in the durability
analysis, but IM in the cardia was not. The presence of IM in these locations was determined
according to the descriptions in the manuscripts. Efficacy outcomes were tabulated
according to baseline histology where available. Progression to EAC during treatment was
recorded as well. The primary durability outcome was recurrence of IM defined
histologically after CE-IM. The presence of dysplasia or EAC at the time of recurrence also
was recorded. Adverse events (most commonly strictures, pain, and bleeding) were recorded
as secondary outcomes. These were ascertained based on the individual study definitions of
adverse events.
Statistical Analysis
We calculated the proportion of patients who met the primary efficacy and durability
outcomes in each study. The denominator for the IM recurrence durability outcome
comprised only those patients who had achieved CE-IM after RFA. The proportion of
patients who achieved CE-IM and CE-D was calculated for each pretreatment histologic
group, and unadjusted risk ratios (RRs) were calculated to compare the outcomes between
these groups, with low-grade dysplasia (LGD) as the comparator. LGD was chosen as the
comparison group because it was present in more studies than NDBE and because it is the
lowest grade of dysplasia that can be compared for the CE-D end point.
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Statistical analysis was performed using Stata version 12.1 (StataCorp LP, College Station,
TX) and Open Meta-Analyst (Tufts Medical Center, Boston, MA).18 To determine the
pooled proportion of patients achieving CE-IM and CE-D and the proportion of those who
had IM recurrence after CE-IM, we performed meta-analyses using a random-effects
model.19 We used the Freeman–Tukey double-arcsine transformation for variance
stabilization for meta-analysis of proportions.20 Random-effects models also were used to
estimate the pooled proportion of patients experiencing adverse events and the RR of CE-IM
and CE-D for patients with pretreatment NDBE (for CE-IM only), high-grade dysplasia
(HGD), and intramucosal carcinoma (IMC) compared with LGD. Heterogeneity was
assessed using the I2 statistic, which estimates the percentage of variation across studies
caused by study heterogeneity.21 I2 values of 25%, 50%, and 75% represent low, moderate,
and high levels of heterogeneity, respectively. To identify potential sources of heterogeneity,
analyses were repeated for each subset of the studies obtained by excluding potential
outliers. In addition, analyses were stratified according to whether they were published as an
abstract or peer-reviewed article. Additional stratified analyses were performed by study
quality (score above vs below the median score), design (prospective vs retrospective), and
sample size (above vs below the median sample size). Non-normally distributed continuous
variables were compared using the Wilcoxon rank-sum test. Ninety-five percent confidence




Of the 1191 unique records identified, 1069 were excluded based on title and abstract review
alone (Figure 1). An additional 102 records were excluded after full-text review because of
non-English language (n = 2), no RFA (n = 3), no focal RFA (n = 4), the use of other
ablative therapies (n = 16), no report of either efficacy or durability (n = 15), mean follow-
up period less than 12 months (n = 4), fewer than 20 subjects (n = 3), duplicate reports of
study samples (n = 23), abstracts published before 2011 (n = 30), and no report of follow-up
duration (n = 2). We therefore included 18 efficacy studies of 3802 patients (13 full-text
articles and 5 abstracts),9,10,12,13,15,22–34 and 6 durability studies of 540 patients (5 full-text
articles and 1 abstract).10,11,16,24,25,32
All included studies were published between 2008 and 2012 and were performed in either
North America or Europe (Table 1). One study was an RCT of RFA vs stepwise radical
endoscopic resection.25 Another was a cohort extension of the sham-controlled Ablation of
Intestinal Metaplasia (AIM) RCT,8 in which subjects initially randomized to the sham group
were offered a cross-over to RFA after 1 year with continued follow-up evaluation for both
efficacy and durability in the overall cohort.24 The remaining studies were either prospective
or retrospective cohort studies.
Study Quality
Study quality ranged from 7 to 24 on the Downs and Black17 instrument, with a median of
13.5 (Table 1) of a total possible score of 32. Published articles had a trend toward higher
quality than abstracts (median, 15 vs 11; P = .07). Studies consistently scored well on
description of study aims, description of main findings, clarity in reporting of unplanned
retrospective analyses, appropriate use of statistical tests, and use of accurate main outcome
measures, and consistently scored poorly on generalizability of study sample,
generalizability of treatment, blinding of subjects and assessors, and randomization. In
aggregate, the studies performed the best on the reporting sub-scale and the worst on the
external validity subscale.
ORMAN et al. Page 4














There was substantial variability among the efficacy studies in terms of the allowed
pretreatment histology, BE length restrictions, and RFA protocols (Table 1). Of the 18
studies, 11 included patients with pretreatment NDBE, 14 included LGD, 17 included HGD,
and 10 included IMC. Five studies included all histologic groups, and 1 included only 1
group (NDBE). Five studies specified BE length restrictions, and the specified maximum
ranged from 5 to 12 cm. Two studies required a minimum length of 2 or 3 cm. The protocol
for 9 of the 18 efficacy studies specified the use of circumferential ablation for the initial
treatment session, and the protocol was not reported in 5 studies (1 article and 4 abstracts).
One study required an absence of IM on 2 consecutive endoscopies to qualify as CE-IM32;
the remainder required only 1 endoscopy. Sample sizes ranged from 22 to 2135, although
only 3 of the 18 studies had more than 137 patients. The largest was a report from the US
RFA Registry, which collected data from patients treated at 148 community-based and
academic institutions across the United States.34 The sample size from this study was greater
than all of the other studies combined. Follow-up evaluation ranged from 12 to 31 months,
with a median of 20.5 months. Two studies did not specify an exact follow-up duration but
were noted to be longer than 12 months.
Patient and treatment characteristics in the efficacy studies are shown in Table 2. A total of
41% of patients with reported pretreatment histology had NDBE, 23% had LGD, 31% had
HGD, and 6% had IMC. Mean age was in the 60s for most studies (range, 56–71 y). Men
comprised 66% to 91% of patients in the studies (mean, 80%). Mean BE length ranged from
3 to 8 cm. Patients were treated with 1 to 3.4 RFA sessions on average, with 2 to 3 sessions
in most studies. The vast majority of studied patients received circumferential ablation. Only
4 of 11 studies reported fewer than 100% use of circumferential RFA, and none reported
less than 50%. In contrast, there was wide variability in the use of EMR, ranging from 0% to
96%.
Durability Study Characteristics
Details of the durability studies are shown in Table 1. The abstract included patients with
any pretreatment histology, whereas the published articles were more restrictive. All but 1
study included patients with dysplasia. Similar to the efficacy studies, BE length restrictions
were variable. With the exception of the AIM II cohort, which specified a single
surveillance endoscopy 5 years after starting treatment for NDBE,11 surveillance protocols
were similar across studies in terms of timing. Most specified surveillance endoscopy at 6
and 12 months after treatment, then annually, with several deviations according to the
pretreatment grade of dysplasia. However, the protocols differed in their specification of
cardia biopsies, and only 3 of 6 started follow-up evaluation at the first post-treatment
endoscopy with biopsies showing eradication. Two started follow-up evaluation at the last
treatment session, and 1 started after eradication was confirmed on a second post-treatment
endoscopy with biopsies. The median sample size was 80 (range, 20–218), and the median
follow-up period was 16.5 months (range, 13–51 mo).
Pretreatment histology distributions varied substantially, although HGD was well
represented in most of the durability studies (Table 2). Twenty-seven percent of patients
with reported pretreatment histology had NDBE, 13% had LGD, 52% had HGD, and 8%
had IMC. Similar to the efficacy studies, the mean age was in the 60s for most studies, most
subjects were male, and the mean BE length was between 3 and 8 cm. Only 4 of the studies
reported the number of surveillance sessions, which was between 1 and 3.
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The pooled percentage of patients achieving CE-IM was 78% in the random-effects model
(95% CI, 70%–86%) and was slightly higher among published articles compared with
abstracts (Figure 2A). Three of the 18 efficacy studies reported point estimates of 50% or
less, whereas 6 studies reported CE-IM of more than 90%. Studies with quality scores above
the median had a greater percentage with CE-IM (84%; 95% CI, 77%–90%) than the lower-
quality studies (68%; 95% CI, 51%–83%). Similarly, the prospective studies had a greater
percentage with CE-IM (84%; 95% CI, 71%–93%) than the retrospective studies (71%; 95%
CI, 58%–82%). CE-IM did not differ by study sample size.
CE-D was achieved in 91% of patients (95% CI, 87%–95%) in the random-effects model
and did not differ substantially between published articles and abstracts (Figure 2B). CE-D
also was unchanged after stratification by study quality, design, and sample size.
Response to therapy varied according to pretreatment histology (Table 3). Patients with
pretreatment HGD were less likely than patients with LGD to achieve CE-IM (RR, 0.92;
95% CI, 0.87–0.98) and CE-D (RR, 0.94; 95% CI, 0.91–0.97). CE-D also was less likely to
occur for patients with IMC compared with patients with LGD, although this difference was
not statistically significant (RR, 0.94; 95% CI, 0.87–1.01). CE-IM was more likely to occur
in patients with NDBE, although this difference also was not statistically significant (RR,
1.12; 95% CI, 0.90–1.40).
A total of 9 patients in 4 studies9,15,24,27 progressed to EAC during treatment, for an overall
risk of 0.1% per year.
Durability Outcomes
After CE-IM, IM recurred in 13% (95% CI, 9%–18%) (Figure 3) and was not substantially
different when the abstract was excluded (11%; 95% CI, 8%–15%). Higher-quality studies
had lower recurrences (11%; 95% CI, 7%–16%) than lower-quality studies (17%; 95% CI,
13%–22%). IM recurrence was similar in larger and smaller studies. At recurrence,
dysplasia was noted in 5 patients from 1 study16 and EAC was noted in 4 patients from 2
studies,16,24 for an overall risk of 0.9% and 0.7%, respectively, over 1.5 years.
Adverse Events
Strictures were the most common reported adverse event (pooled estimate, 5%; 95% CI,
3%–7%), followed by pain (3%; 95% CI, 1%–6%) and bleeding (1%; 95% CI, 1%–2%).
Pain was more common in abstracts (8%; 95% CI, 0%–31%) and prospective studies (6%;
95% CI, 1%–13%) compared with published articles (3%; 95% CI, 1%–5%) and
retrospective studies (2%; 95% CI, 1%–4%), mostly as a result of 1 outlier study that
reported pain in 44% of patients (Martinek et al).33 Other adverse events were similar in
stratified analyses.
Heterogeneity
There was substantial heterogeneity in the primary efficacy and durability outcomes, with I2
values of 96% for CE-IM, 78% for CE-D, and 46% for IM recurrence (Figures 2 and 3).
Stratification by publication status (article vs abstract) partially attenuated the heterogeneity
in the efficacy analyses; however, in general, heterogeneity persisted. Stratification by
publication status could not be performed for IM recurrence because there was only 1
abstract examining this outcome. Stratification of CE-IM by quality, design, and sample size
did not reduce heterogeneity significantly (minimum I2 = 85% for high-quality studies). For
CE-D, heterogeneity for small studies was low (I2 = 0%) but was otherwise substantial, with
the next lowest value of 62% for prospective studies. Heterogeneity was low for IM
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recurrence in low- (I2 = 0%) and high-quality (I2 = 26%) studies considered separately and
in small studies (I2 = 0%). To search for specific sources of heterogeneity, summary effect
estimates were regenerated while excluding 1 study at a time from the analyses. In no case
did the exclusion of a single study result in a shift of greater than 3% in the summary
estimate, suggesting that no single outlier was the predominant cause of the heterogeneity
noted in the results.
There was also heterogeneity in the model comparing CE-IM between patients with
pretreatment NDBE and LGD (Table 3). Excluding the study by Lyday et al13 resulted in a
statistically significant difference favoring NDBE (RR 1.21; 95% CI, 1.13–1.30; I2 = 0%).
There was significant heterogeneity for the estimate of strictures (I2 = 59%) and pain (I2 =
85%). Stratification of studies estimating strictures resulted in improved heterogeneity for
prospective studies (I2 = 35%) and abstracts (I2 = 0%). Stratification did not resolve the
heterogeneity in the pooled estimate of pain. Excluding the Martinek et al33 study reduced
the pain estimate from 3% to 2% and did not markedly improve heterogeneity (I2 = 74%).
Discussion
RFA has emerged as a preferred method for the endoscopic ablation of BE.1 It safely and
effectively eradicates dysplasia and IM, and for those with HGD it reduces progression to
cancer.8 In this systematic review and meta-analysis, we estimated the proportion of patients
treated with RFA who achieved eradication of dysplasia and IM and the proportion of
patients with recurrence of IM after successful treatment. We found that RFA resulted in
CE-D in 91% of patients and CE-IM in 78% of patients, and that 13% of patients had
recurrent IM after successful eradication.
To make appropriate informed decisions about the use of RFA, patients and providers need
to be well versed in the risks and benefits of the procedure. However, making predictions
about treatment outcome can be difficult when based on single-center studies with small
sample sizes and large standard errors. This systematic review provides further guidance for
these decisions by combining the results of several studies. Although heterogeneity was
substantial, the pooled estimates likely are representative of the true efficacy and
effectiveness of RFA as estimated for baseline degree of dysplasia. CE-D and CE-IM
proportions reported here are similar to the AIM dysplasia RCT of RFA compared with
sham ablation for dysplastic BE.8 That trial was conducted rigorously, with close follow-up
evaluation of subjects, and therefore may be the best estimate of efficacy in ideal
circumstances. In contrast, the US RFA Registry contains data collected from 148 academic
and nonacademic institutions across the country, without standardized treatment protocols.34
Our pooled CE-D and CE-IM proportions also were similar to this registry, reflecting a good
estimate of effectiveness in a real-world setting. In addition, exclusion of individual studies
did not change the pooled point estimates substantially, so the estimates appear robust to the
effects of individual studies despite the large amount of heterogeneity.
We found that efficacy differed based on the baseline degree of dysplasia, with a trend
toward reduced efficacy for those with more advanced histology (Table 3). This relationship
was seen in some studies,9,12,24,34 but not others,13,15 and the reason for such a relationship
is not entirely clear. RFA using standard energy settings results in a uniform depth of tissue
destruction.35 Therefore, in the absence of nodularity or invasive cancer, RFA might be
expected to result in equivalent eradication of IM regardless of the degree of dysplasia. One
possible explanation for this finding is that histology is a surrogate marker of BE length,
with greater length associated with more advanced histology.36 CE-IM rates are lower in
patients with longer BE segments because of the greater surface area that must be treated
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and the greater likelihood of missing a portion of BE.8,13,15 It was not possible to adjust our
findings for BE length because studies vary in the BE length cut-off value used for
comparison. However, a meta-analysis of individual patient-level data potentially could
resolve this issue. Another potential explanation is that HGD is more likely than LGD or
NDBE to harbor malignancy,37 which is also more likely to penetrate into the submucosa,
beyond the depth of ablation.38 This explanation is less likely because such failures of CE-
IM would be expected to translate into increased progression to EAC, which nevertheless
was low in this review. Finally, BE of more advanced histology may be qualitatively
different than NDBE with respect to its susceptibility to destruction by thermal methods.
Whether the same mutations that cause the phenotypic aberration of these cells also might
confer resistance to destruction by RFA is unclear.
EAC developed in 9 of 3802 patients during 20.5 months of treatment (0.1% per year). Of
the 7 patients with pretreatment histology reported, 1 patient had LGD, 5 patients had HGD,
and 1 patient had IMC. Assuming a worst-case scenario allotting the remaining 2 cases to
each group, the worst rate of progression to EAC would be 0.09% for NDBE, 0.2% for
LGD, 0.4% for HGD, and 0.9% for IMC. In comparison, studies have shown a 0.12% to
0.6% annual risk of EAC for patients with NDBE3,36 and annual risks of 1.7% and 6.6% for
patients with LGD and HGD, respectively.39 Although the rates of progression reported in
postablation patients in this review appear lower than those reported in natural history
studies, direct comparisons between the 2 groups cannot be made owing to potential
differences in patient populations, as well as the varied follow-up periods and surveillance
protocols.
Durability of RFA appeared reasonable with a low, but not inconsequential, rate of IM
recurrence. This finding suggests that the majority of patients who achieve CE-IM will
continue to maintain squamous epithelium after 1.5 years of follow-up evaluation. However,
it also should serve as a warning that patients need to be maintained in a surveillance
program after completion of therapy because a sizeable minority (9%–18%) did develop
recurrence, and EAC occurred in 0.7%.
The safety profile of RFA showed strictures in 5% of patients. This figure compares
favorably with other endoscopic interventions for BE. Lewis et al40 reported symptomatic
stricture formation in 25% of patients undergoing EMR monotherapy at a single center. In a
multicenter study of photodynamic therapy, 36% developed esophageal strictures.41
Strictures arose in only 3% of patients treated with endoscopic spray cryotherapy in a
multicenter cohort study,6 although there are less data for this modality compared with RFA.
In a head-to-head comparison, strictures developed in 88% of patients treated with stepwise
radical endoscopic resection compared with just 14% of those treated with RFA.25
Interestingly, pain was reported in only 3% of patients. However, there was significant
heterogeneity in the estimate of pain (I2 = 85%), with 2 outlier estimates of 15% and
44%.22,33 This heterogeneity may be caused by differences in ascertainment of pain because
modest discomfort is common after RFA. In the AIM Dysplasia Trial, the median chest pain
score after RFA was 23 on a visual analogue scale from 0 to 100.8 However, only 2 patients
were classified as having an adverse event related to chest pain or discomfort. In clinical
practice, practitioners often prescribe oral narcotics and viscous lidocaine after RFA
sessions.
There were several limitations of this systematic review. The quality of the included studies
was suboptimal, with a median score of 13.5 of a total possible score of 32.17 Only 2 studies
had scores greater than 20. External validity was particularly poor, with 15 of 20 studies
scoring zero on this subscale. This deficiency is not surprising because most of the studies
ORMAN et al. Page 8













were performed in referral centers with expertise in RFA. However, because summary
estimates were comparable with the US RFA Registry34 and with a multicenter community
practice registry,13 these results may be generalizable to the broader population. In addition,
stratification by quality actually showed improved CE-IM and IM recurrence for the higher-
quality studies. This review also was limited by substantial heterogeneity. I2 values for the
primary efficacy and durability outcomes were moderate to high and are likely owing to
differences in patient samples, study settings and protocols, and provider factors. This
heterogeneity calls into question the reliability of the estimates, which will need to be
confirmed as experience with RFA continues to accumulate in the future. However, the fact
that estimates did not vary greatly with the inclusion and exclusion of the US RFA Registry
data (which comprised more than half of the overall patients in this review), or with the
removal of any other single study, speaks to the reliability of our findings despite the
heterogeneity. Furthermore, although our analysis represents a detailed documentation of the
data available to date, it can be no stronger than the underlying data, and the precision of our
effect estimates may change as new data become available. Finally, the retrospective nature
of several studies may have resulted in an underestimate of adverse events.
In summary, in this systematic review and meta-analysis of efficacy and durability studies of
RFA for BE, we found that a high proportion of treated patients achieve CE-D and CE-IM
and that most patients maintain the neosquamous epithelium after successful treatment
without IM recurrence. We also observed a low incidence of adverse events with RFA.
Despite the poor quality and limited external validity of the studies, these data may be
helpful for patients and providers in weighing the absolute risks and benefits of this therapy.
Further analysis and follow-up evaluation of the US RFA Registry in particular will be
helpful in enhancing generalizability and defining RFA effectiveness in the broader
population of patients with BE.
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Abbreviations used in this paper
AIM Ablation of Intestinal Metaplasia
BE Barrett’s esophagus
CE-D complete eradication of dysplasia
CE-IM complete eradication of intestinal metaplasia
CI confidence interval
EAC esophageal adenocarcinoma





NDBE nondysplastic Barrett’s esophagus
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RCT randomized controlled trial
RR risk ratio
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Forest plots of the proportion of patients achieving (A) CE-IM and (B) CE-D after treatment
of BE with RFA, stratified according to publication as a peer-reviewed article vs abstract.
ORMAN et al. Page 14














Forest plot of the proportion of patients with recurrent IM after RFA-induced CE-IM.
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